PRACA PRZEGLĄDOWA
Zmęczenie- niedoceniany objaw łuszczycowego zapalenia stawów.
Data nadesłania: 03-04-2017
Data akceptacji: 09-05-2017
Data publikacji online: 18-07-2017
Data publikacji: 30-06-2017
Reumatologia 2017;55(3):125-130
SŁOWA KLUCZOWE
DZIEDZINY
Spondyloartropatie - etiologia, patogeneza, obraz kliniczny i leczenieOcena aktywności choroby i jakości życia w chorobach reumatycznych
STRESZCZENIE
The nature of fatigue is very complex and involves physiological, psychological and social phenomena at the same time, and the mechanisms leading to occurrence and severity of fatigue are still poorly understood. The condition of chronic inflammation associated with psoriatic arthritis can be regarded as a potential factor affecting development of fatigue. Only a few studies so far have focused on the occurrence of fatigue in psoriatic arthritis. The problem of chronic fatigue is underestimated in everyday clinical practice. Identification and analysis of subjective fatigue components in each patient can provide an objective basis for optimal fatigue treatment in daily practice. This review presents a definition of chronic fatigue and describes mechanisms that may be associated with development of fatigue, highlighting the role of chronic inflammation, selected fatigue measurement methods and relations of fatigue occurrence with clinical aspects of psoriatic arthritis.
REFERENCJE (60)
1.
Dupond JL. Fatigue in patients with rheumatic diseases. Joint Bone Spine 2011; 78: 156-160.
2.
Boksem MA, Tops M. Mental fatigue: costs and benefits. Brain Res Rev 2008, 59: 125-139.
3.
Nikolaus S, Bode C, Taal E, et al. Fatigue and factors related to fatigue in rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) 2013; 65: 1128-1146.
4.
Norheim KB, Jonsson G, Omdal R. Biological mechanisms of chronic fatigue. Rheumatology (Oxford) 2011; 50: 1009-1018.
6.
Husted JA, Tom BD, Schentag CT, et al. Occurrence and correlates of fatigue in psoriatic arthritis. Ann Rheum Dis 2009; 68: 1553-1558.
7.
Hewlett S, Cockshott Z, Byron M, et al. Patients’ perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum 2005; 53: 697-702.
8.
Konsman JP, Parnet P, Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Trends Neurosci 2002; 25: 154-159.
9.
Quan N, Banks WA. Brain-immune communication pathways. Brain Behav Immun 2007; 21: 727-735.
10.
Vitkovic L, Konsman JP, Bockaert J, et al. Cytokine signals propagate through the brain. Mol Psychiatr 2000; 5: 604-615.
11.
Murr C, Widner B, Wirleitner B, et al. Neopterin as a marker for immune system activation. Curr Drug Metab 2002; 3: 175-187.
12.
Capuron L, Schroecksnadel S, Feart C, et al. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry 2011; 70: 175-182.
13.
O’Connor JC, Andre C, Wang Y, et al. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to Bacillus Calmette-Guerin. J Neurosci 2009; 29: 4200-4209.
14.
Moron JA, Zakharova I, Ferrer JV, et al. Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci 2003; 23: 8480-8488.
15.
Malynn S, Campos-Torres A, Moynagh P, et al. The pro-inflammatory cytokine TNF-alpha regulates the activity and expression of the serotonin transporter (SERT) in astrocytes. Neurochem Res 2013; 38: 694-704.
16.
Norden DM, Bicer S, Clark Y, et al. Tumor growth increases neuroinflammation, fatigue and depressive-like behavior prior to alterations in muscle function. Brain Behav Immun 2014; 43: 76-85.
17.
Bluthe RM, Beaudu C, Kelley KW, et al. Differential effects of IL-1ra on sickness behavior and weight loss induced by IL-1 in rats. Brain Res 1995; 677: 171-176.
18.
Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005; 104: 788-793.
19.
Reyes-Gibby CC, Wang J, Spitz M, et al. Genetic variations in interleukin-8 and interleukin-10 are associated with pain, depressed mood, and fatigue in lung cancer patients. J Pain Symptom Manage 2013; 6: 161-172.
20.
Irwin MR. Inflammation at the intersection of behavior and somatic symptoms. Psychiatr Clin North Am 2013; 34: 605-620.
21.
Bower JE. Cancer-related fatigue: links with inflammation in cancer patients and survivors. Brain Behav Immun 2007; 21: 863-871.
22.
Neu D, Mairesse O, Montana X, et al. Dimensions of pure chronic fatigue: psychophysical, cognitive and biological correlates in the chronic fatigue syndrome. Eur J Appl Physiol 2014; 114: 1841-1851.
23.
Heinzelmann M, Lee H, Rak H, et al. Sleep restoration is associated with reduced plasma C-reactive protein and depression symptoms in military personnel with sleep disturbance after deployment. Sleep Med 2014; 15: 1565-1570.
24.
Chauffier K, Salliot C, Berenbaum F, et al. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology (Oxford) 2012; 51: 60-68.
25.
Capuron L, Castanon N. Role of inflammation in the development of neuropsychiatric symptom domains: evidence and mechanisms. Curr Top Behav Neurosci 2017; 31: 31-44.
27.
Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 2010; 332: 1351-1362.
28.
Wolfe F, Michaud K, Pincus T. Preliminary evaluation of a visual analog function scale for use in rheumatoid arthritis. J Rheumatol 2005; 32: 1261-1266.
29.
Ware JE, Kosinski M, Keller SD. SF-36 Health Survey: Manual and Interpretation Guide. MA, USA: The Health Institute, New England Medical Center; 1983.
30.
Belza BL, Henke CJ, Yelin EH, et al. Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res 1993, 42: 93-99.
31.
Cella D, Yount S, Sorrensen M, et al. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 811-819.
32.
Chandran V, Bhella S, Schentag C, et al. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheumatic Dis 2007; 66: 936-939.
33.
Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-1123.
34.
Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64: 18-23.
35.
Meyer N, Paul C, Feneron D et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol 2010; 24: 1075-1082.
36.
Heller MM, Wong JW, Nguyen TV, et al. Quality-of-life instruments: Evaluation of the impact of psoriasis on patients. Dermatol Clin 2012; 30: 281-291.
37.
Jankovic S, Raznatovic M, Marinkovic J, et al. Health-related quality of life in patients with psoriasis. J Cutan Med Surg 2011; 15: 29-36.
38.
Armstrong AW, Schupp C, Wu J, et al. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS One 2012; 7: e52935.
39.
McDonough E, Ayearst R, Eder L, et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol 2014; 41: 887-896.
40.
Skoie IM, Dalen I, Ternowitz T, et al. Fatigue in psoriasis – a controlled study. Br J Dermatol 2017; doi: 10.1111/bjd.15375.
41.
Verhoeven EW, Kraaimaat FW, van de Kerkhof PC, et al. Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice. Br J Dermatol 2007; 156: 1346-1349.
42.
Tobin AM, Sadlier M, Collins P, et al. Fatigue as a symptom in psoriasis and psoriatic arthritis: an observational study. Br J Dermatol 2016; doi: 10.1111/bjd.15258.
43.
Thaci D, Galimberti R, Amaya-Guerra M, et al. Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial. J Eur Acad Dermatol Venereol 2014; 28: 900-906.
44.
Krueger GG, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005; 153: 1192-1199.
45.
Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006; 154: 1161-1168.
46.
Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35.
47.
Krishnan R, Cella D, Leonardi C, et al. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br J Dermatol 2007; 157: 1275-1277.
48.
Daudén E, Griffiths CE, Ortonne JP, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol 2009; 23: 1374-1382.
49.
Reich K, Segaert S, Van de Kerkhof P, et al. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology 2009; 219: 239-249.
50.
Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010; 162: 137-146.
51.
Papp K, Crowley J, Ortonne JP, et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol 2011; 164: 434-441.
52.
Nakagawa H, Schenkel B, Kato M, et al. Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: results from a randomized, double blind, placebo-controlled phase 2/3 trial. J Dermatol 2012; 39: 761-769.
53.
Kalb RE, Blauvelt A, Sofen HL, et al. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial. J Drugs Dermatol 2013; 12: 874-880.
54.
Eder L, Polachek A, Rosen CF, et al. The development of PsA in patients with psoriasis is preceded by a period of non-specific musculoskeletal symptoms: A prospective cohort study. Arthritis Rheumatol 2017; 69: 622-629.
55.
Husted JA, Tom BD, Farewell VT, et al. Longitudinal analysis of fatigue in psoriatic arthritis. J Rheumatol 2010, 37: 1878-1884.
56.
Gudu T, Etcheto A, de Wit M, et al. Fatigue in psoriatic arthritis – a cross-sectional study of 246 patients from 13 countries. Joint Bone Spine 2016; 83: 439-443.
57.
Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2007; 13: 237-251.
58.
Singh H, Arya S, Talapatra P, et al. Assessment of fatigue in rheumatoid arthritis (by Functional Assessment of Chronic Illness Therapy-Fatigue score) and its relation to disease activity and anemia. J Clin Rheumatol 2014; 20: 87-90.
59.
Vincent A, Benzo RP, Whipple MO, et al. Beyond pain in fibromyalgia: insights into the symptom of fatigue. Arthritis Res Ther 2013; 15: 221.
60.
Repping-Wuts H, van Riel P, van Achterberg T. Rheumatologists’ knowledge, attitude and current management of fatigue in patients with rheumatoid arthritis (RA). Clin Rheumatol 2008; 27: 1549-1555.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Udostępnij
ARTYKUŁ POWIĄZANY
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
Przetwarzamy dane osobowe zbierane podczas odwiedzania serwisu. Realizacja funkcji pozyskiwania informacji o użytkownikach i ich zachowaniu odbywa się poprzez dobrowolnie wprowadzone w formularzach informacje oraz zapisywanie w urządzeniach końcowych plików cookies (tzw. ciasteczka). Dane, w tym pliki cookies, wykorzystywane są w celu realizacji usług, zapewnienia wygodnego korzystania ze strony oraz w celu monitorowania ruchu zgodnie z Polityką prywatności. Dane są także zbierane i przetwarzane przez narzędzie Google Analytics (więcej).
Możesz zmienić ustawienia cookies w swojej przeglądarce. Ograniczenie stosowania plików cookies w konfiguracji przeglądarki może wpłynąć na niektóre funkcjonalności dostępne na stronie.
Możesz zmienić ustawienia cookies w swojej przeglądarce. Ograniczenie stosowania plików cookies w konfiguracji przeglądarki może wpłynąć na niektóre funkcjonalności dostępne na stronie.
